Today's Rundown Featured Story | | | Tuesday, November 27, 2018 Abeona Therapeutics CEO Carsten Thiel has been sacked after an investigation into “allegations of misconduct towards colleagues” and will be replaced immediately by head of R&D João Siffert. |
|
|
Top Stories Monday, November 26, 2018 Roivant and Cincinnati Children’s Hospital Medical Center are launching Aruvant Sciences, which will focus on developing gene therapies for blood diseases, starting with sickle cell disease and beta-thalassemia. Tuesday, November 27, 2018 Halozyme has dropped the progression-free survival (PFS) co-primary endpoint from its phase 3 trial of PEGPH20 in metastatic pancreatic cancer. The change ties the fate of the trial to an overall survival endpoint that is expected to read out in the second half of 2019. Monday, November 26, 2018 A diagnosis of chronic lymphocytic leukemia (CLL) can mean a long road with many twists and turns as patients try to achieve long-term remission from this chronic, complex and progressive form of blood cancer. Monday, November 26, 2018 Rheostat Therapeutics reeled in a $23 million series A round to develop treatments for neurodegenerative and rare diseases by targeting autophagy, the cell’s garbage disposal. The new capital will push its programs toward clinical trials and support biomarker studies. Tuesday, November 27, 2018 BeiGene has paid Zymeworks $40 million for the Asian rights to HER2-targeted bispecific antibodies ZW25 and ZW49. The agreement gives Zymeworks upfront cash, a potential ongoing income stream and a global development partner. Tuesday, November 27, 2018 Janssen Research & Development’s global head of discovery, Dashyant Dhanak, Ph.D., is joining Incyte to serve as its chief scientific officer, effective Dec. 10. He will take over for Reid Huber, Ph.D., who has moved on to become a partner at Third Rock Ventures. Tuesday, November 20, 2018 Just two weeks after Sanofi laid out $125 million to take a stake in two RIPK1 inhibitors being developed by Denali, the two companies are advancing one of those drugs into clinical trials in three of the toughest-to-treat neurological disorders. | This week's sponsor is Johnson & Johnson Innovation. | |  | |
Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. | 
